Verrica Pharmaceuticals Reports Q3 2024 EPS of -0.49 and Revenue of -1.9 Million, Misses Estimates
| VRCA Stock | USD 0.99 0.10 11.24% |
About 73 percent of all Verrica Pharmaceuticals' investors are curious in acquiring. The analysis of overall sentiment of trading Verrica Pharmaceuticals stock suggests that a large number of investors are confidant at this time. The current market sentiment, together with Verrica Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Verrica Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Verrica |
Revenue Reported negative net product revenue of 1.9 million, significantly below the estimated revenue of 4.63 million, due to a provision for product retu
Read at gurufocus.com
 |